人工智能混合生存评估,用于晚期心力衰竭患者,患有功能障碍
Ge Zhang1,2,3, Zeyu Wang1,2,3, Zhuang Tong4
1Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Nature communications
|August 8, 2024
概括
这项研究介绍了AIHFLevel,这是一个人工智能系统,用于预测患有功能障碍的高级心力衰竭患者的生存率. 它提供了一个比现有方法更准确和更适用于临床的预后工具.
科学领域:
- 心脏病学 心脏病学
- 人工智能的人工智能
- 医学预测 医学预测
背景情况:
- 功能障碍 (RD) 复杂化了晚期心力衰竭 (AHF) 的预后.
- 目前对AHF/RD患者的预后评估存在偏见和有限的临床效用.
- 开发准确和适用的生存预测模型对于AHF/RD管理至关重要.
研究的目的:
- 开发和验证可解释的人工智能 (AI) 混合建模框架,用于对AHF和RD患者的生存评估.
- 创建一个强大的和临床上适用的预后工具,克服现有方法的局限性.
- 为医疗保健专业人员提供一个增强的工具,用于持续的风险监测和精确的风险概况.
主要方法:
- 开发了一个AI混合建模框架,整合了12个学习者,具有不同的特征选择方法.
- 评估了132个潜在的建模方案,以确定最优化的战略.
- 基于概率值的预后分层使用了条件推断生存树.
主要成果:
- 开发的AI系统AIHFLevel在歧视,校准,概括和临床影响方面表现出强的表现.
- 在预测AHF/RD患者的生存率方面,AIHFLevel的表现优于现有的预后模型,临床特征和生物标志物.
- 一个开放访问的网站 (www.hf-ai-survival.com) 启动,以促进临床应用.
结论:
- AIHFLevel为AHF/RD患者提供了可靠和可解释的生存评估系统.
- 与当前方法相比,AIHFLevel系统提供了优越的预后能力.
- 可访问的在线平台为临床医生提供了用于患者风险分层和管理的先进工具.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:22Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
01:11Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326